Purpose The purpose of this study was to evaluate altered pulmonary function retrospectively after RFA. Methods This retrospective study comprised 41 ablation sessions for 39 patients (22 men and 17 women; mean age, 64.8 years). Vital capacity (VC) and forced expiratory volume in 1 s (FEV 1 ) at 1 and 3 months after RFA were compared with the baseline (i.e., values before RFA). To evaluate the factors that influenced impaired pulmonary function, univariate analysis was performed by using multiple variables. If two or more variables were indicated as statistically significant by univariate analysis, these variables were subjected to multivariate analysis to identify independent factors. Results The mean VC and FEV 1 before RFA and 1 and 3 months after RFA were 3.04 and 2.24 l, 2.79 and 2.11 l, and 2.85 and 2.13 l, respectively. The values at 1 and 3 months were significantly lower than the baseline. Severe pleuritis after RFA was identified as the independent factor influencing impaired VC at 1 month (P = 0.003). For impaired FEV 1 at 1 month, only severe pleuritis (P = 0.01) was statistically significant by univariate analysis. At 3 months, severe pleuritis (VC, P = 0.019; FEV 1 , P = 0.003) and an ablated parenchymal volume C20 cm 3 (VC, P = 0.047; FEV 1 , P = 0.038) were independent factors for impaired VC and FEV 1 . Conclusions Pulmonary function decreased after RFA. RFA-induced severe pleuritis and ablation of a large volume of marginal parenchyma were associated with impaired pulmonary function.
Introduction
Radiofrequency ablation (RFA) is gaining popularity for the treatment of lung cancer, because it is technically simple and safe, providing good local control. Midterm survival after this treatment seems promising: 68% at 2 years [1] , 75% at 2 years [2] , and 74% at 3 years [3] for patients with clinical stage I non-small cell lung cancer; and 66% at 2 years [2] and 46-48% [4] [5] [6] at 3 years for patients with metastatic colorectal cancer. To minimize the risk of local tumor progression, ablation should be performed with adequate parenchymal margin. However, ablation of marginal parenchyma might lead to pulmonary function loss. Furthermore, if severe pleuritis is induced by RFA, subsequently occurring pleural adhesion may impair pulmonary function. However, influence of RFA on pulmonary function has not been fully investigated. Therefore, the purpose of this study was to evaluate altered pulmonary function retrospectively after RFA. Furthermore, factors influencing impaired pulmonary function after RFA were investigated.
Methods and Materials
Institutional review board approval of Okayama University Hospital (approval number: 90) and informed consent from patients were obtained for RFA of lung cancer. Our institutional review board gave us the approval and waived informed consent for this kind of retrospective study (approval number: 293).
Study Endpoints and Population
This study was retrospectively designed. Study endpoints included post-RFA altered pulmonary function and factors that influenced impaired pulmonary function after RFA. The inclusion criteria for this study were as follows: (1) chest CT and pulmonary function test with spirometry were performed within 1 week before RFA and 1 and 3 months after RFA; (2) no other therapy, such as systemic chemotherapy, radiation therapy, surgical treatment, or another RFA session was given within 3 months before and after RFA; and (3) no other pulmonary event (e.g., pneumonia, atelectasis, and pulmonary embolism) occurred within 3 months after RFA. This study focused on 39 patients (22 men and 17 women; mean age, 64.8 years; range, 35-78 years) who fulfilled the inclusion criteria between February 2007 and December 2009. A total of 51 lung tumors were treated during 41 RFA sessions. Thirty-one sessions (76%) involved a single tumor, and 10 sessions (24%) involved multiple tumors (mean number of tumors ablated per session 1.3; range 1-3). Ten patients had primary lung cancer, and 29 had secondary lung cancer, which was primarily from colorectal cancer (n = 14), primary lung cancer (n = 8), hepatocellular carcinoma (n = 3), renal cell carcinoma (n = 1), and others (n = 3).
RFA Techniques
The details of the procedure have been described previously [7] . Briefly, the procedure was performed percutaneously under CT fluoroscopic guidance (Asteion; Toshiba, Tokyo, Japan). All patients underwent chest CT immediately before RFA to target the tumor. REA was performed under local anesthesia alone (n = 20) or local plus epidural anesthesia (n = 21); general anesthesia was not used for RFA. After an anesthetic was introduced, the electrode was advanced into the tumor and connected to an RFA generator, and then, RF energy was applied. We used two types of electrodes: an internally cooled electrode (Cool-tip; Covidien, Mansfield, MA) for eight tumors, and a multi-tined expandable electrode (LeVeen; Boston Scientific, Natick, MA) for 43 tumors. The procedure was designed to treat the entire tumor and achieve an ablative margin of at least 0.5 cm around the tumors. After the procedure, chest CT images were obtained to assess the procedure.
A chest radiograph was obtained 3 h later and the following morning to evaluate procedural complications. On the following morning, blood cell count and blood chemistry were examined. Thereafter, chest radiograph and blood examination were repeated whenever deemed necessary. Chest CT images were obtained 1 and 3 months after RFA to assess local efficacy.
Evaluation of Altered Pulmonary Function After RFA
Pulmonary function values used for evaluation were vital capacity (VC) and forced expiratory volume in 1 s (FEV 1 ). The proportions of the pulmonary function values at 1 and 3 months after RFA to baseline values (i.e., before RFA) were calculated. Furthermore, the values at each time point were compared with those at other time points by using 1-factor repeated measures ANOVA.
Evaluation of Factors Influencing Impaired Pulmonary Function After RFA We collected multiple variables, including age, gender, presence of pulmonary emphysema, occurrence of severe pleuritis after RFA, percentage of vital capacity to predicted value before RFA (pre-RFA %VC), percentage of FEV 1 to forced vital capacity before RFA (pre-RFA FEV 1 %), distance to the nearest pleura from tumor, tumor type, tumor volume, ablated parenchymal volume, electrode type, and ablation time. When multiple tumors were treated during a session, the shorter or shortest distance to the nearest pleura from the tumors was considered; ablation time was the sum of RF energy applied for all treated tumors. Severe pleuritis was deemed to occur after RFA, when the following criteria were fulfilled: (1) pleural effusion was observed at the treated side on the chest radiograph obtained within 3 days of RFA; (2) C-reactive protein level was [10 mg/dl within 3 days of RFA; and (3) no other cause of inflammation.
The tumor volume and ablation zone volume were calculated using the following formula: p/6 9 maximum diameter 9 diameter perpendicular to the maximum diameter 9 diameter in craniocaudal direction. Tumor diameters were measured on pre-procedural axial CT images. Ablation zone diameters were measured on axial CT images obtained immediately after RFA. The ablation zone was recognized as ground-glass opacity surrounding the tumors [8] . The maximum diameter and diameter perpendicular to the maximum diameter were measured on the image of maximal cross-section. The diameter in the craniocaudal direction was calculated by multiplying the number of slice images in which the tumor and ablation zone were demonstrated by slice thickness. The ablated parenchymal volume was calculated by subtracting the tumor volume from the ablation zone volume.
According to the category or value of each variable, the 41 sessions were categorized into 2 groups. Age was categorized using mean value as a threshold. Tumor volume, ablated parenchymal volume, and ablation time was categorized by using median value as a threshold. First, the proportions of pulmonary function values at 1 and 3 months after RFA to baseline values were compared between the two groups by univariate analysis by using the Student's t test. Subsequently, if two or more variables were found to be significantly different by the analyses, multiple linear regression analysis was performed by using such variables to determine an independent factor. All analyses were performed using the Statistical Package for the Social Sciences (SPSS) software (version 11.0; SPSS Inc, Chicago, IL). For all analyses, P \ 0.05 was considered statistically significant.
Results
The mean tumor volume was 2.7 (range 0.1-16.8) cm 3 , whereas the mean ablation zone volume was 27.9 (range 6.0-99.9) cm 3 ; thus, the mean ablated parenchymal volume was 25.2 (range 5.8-93.7) cm 3 . All 51 ablated tumors were considered to be completely involved in the ablation zone on CT images obtained immediately after RFA. None of the tumors showed local progression until 3 months of RFA. (Fig. 1B) The VC values at 1 and 3 months were significantly lower (P = 0.001 and P = 0.002, respectively) than baseline values. The VC values at 3 months were not significantly different (P = 0.12) from those at 1 month. B The mean FEV 1 values before and after 1 and 3 months of RFA were 2.24 l (range 0.85-3.49 l), 2.11 l (range 0.83-3.41 l), and 2.13 l (range 0.79-3.39 l), respectively. The FEV 1 values at 1 and 3 months were significantly lower (P = 0.001 each) than baseline values. The FEV 1 values at 3 months were not significantly different (P = 1) from those at 1 month and FEV 1 ) than baseline values. The VC and FEV 1 values at 3 months also were significantly lower (P = 0.002 for VC and P = 0.001 for FEV 1 ) than baseline values. The VC and FEV 1 values at 3 months were not significantly different (P = 0.12 for VC and P = 1 for FEV 1 ) from those at 1 month. Any respiratory symptom did not develop after RFA in 37 patients, whereas two patients required home oxygen therapy after RFA. The data on the two cases are shown in Table 1 .
Factors That Influencing Impaired Pulmonary Function after RFA
The results from the Student's t tests used to evaluate factors that influence impaired VC revealed that male gender (P = 0.03), pre-RFA FEV 1 % \70% (P = 0.04), occurrence of severe pleuritis (P \ 0.001), and tumor volume C1.3 cm 3 (P = 0.04) significantly impaired VC at 1 month. At 3 months, male gender (P = 0.046), occurrence of severe pleuritis (P = 0.01), tumor volume C1.3 cm 3 (P = 0.02), and ablated parenchymal volume C20 cm 3 (P = 0.009) significantly impaired VC (Table 2) . Multiple linear regression analysis identified severe pleuritis (P = 0.003), severe pleuritis (P = 0.019), and ablated parenchymal volume C20 cm 3 (P = 0.047) to be independent factors at 1 and 3 months, respectively ( ). The Student's t test showed that only the occurrence of severe pleuritis was significant (P = 0.01) at 1 month and that the occurrence of severe pleuritis (P = 0.002), tumor volume C1.3 cm 3 (P = 0.02), and ablated parenchymal volume C20 cm 3 (P = 0.01) significantly impaired FEV 1 at 3 months (Table 2) . Multiple linear regression analysis showed that both occurrence of severe pleuritis (P = 0.003) and ablated parenchymal volume C20 cm 3 (P = 0.038) were significant independent factors at 3 months ( 
Discussion
Few studies have evaluated the influence of RFA on pulmonary function. Ambrogi et al. [9] had findings similar to our findings, where pulmonary function decreased 1 month after RFA, although not statistically significant, and then recovered to some extent at 3 months. The mean forced VC was 2.63 and 2.80 l at 1 and 3 months, respectively, compared with 2.91 l before RFA; the mean FEV 1 was 1.71 and 1.86 l at 1 and 3 months, respectively, compared with 1.97 l before RFA. The multicenter prospective study by Lencioni et al. [2] also showed impaired pulmonary function after RFA in 22 patients with non-small cell lung cancer with mean forced VC and FEV 1 of 2.6 and 1.7 l, respectively, at 1 month, compared with 2.9 and 1.9 l, respectively, before RFA, although the differences were not statistically significant. In contrast, de Baère et al. [10] reported that pulmonary function did not decrease after RFA; the mean VC and FEV 1 were 2.9 and 2.2 l, respectively, after RFA, compared with 2.9 and 2.2 l, respectively, before RFA. Although our results were similar to the results of previous two studies by Ambrogi et al. and Lencioni et al., those were different from the results of the study by de Baère et al. Although the exact reason for the difference cannot be determined, we speculate that our study included relatively high rate (34%, 14/41) of the patients with pulmonary emphysema that were related to severe pleuritis after RFA and larger ablated parenchymal volume (see Appendix).
Factors that affect pulmonary function by RFA are poorly understood. The results obtained in this study seem to verify our hypothesis that induced severe pleuritis and ablated parenchymal volume are associated with impaired pulmonary function by RFA. We assume that pain and pleural adhesion resulting from severe pleuritis might be related to impaired pulmonary function. Specifically, at 1 month, inflammation due to pleuritis persisted to a degree, and thus, occurrence of severe pleuritis was the most important factor at 1 month. At 3 months, a larger ablated parenchymal volume was another important factor. Ablation followed by coagulation of the parenchyma may lead to functional loss. Furthermore, additional functional loss might occur during the healing process of the ablation zone. This is because shrinkage of the ablation zone may retract the surrounding nonablated parenchyma, resulting in a decrease in alveoli compliance. According to reports on pulmonary function after surgical resection, FEV 1 at 1 and 3 months after lobectomy was 79.5 and 84% of the baseline value, respectively, and FEV 1 at 1 and 3 months after pneumonectomy was 65 and 66% of baseline, respectively [11] . Forced VC and FEV 1 at 2 months after segmentectomy were 89.6 and 90.5% of baseline, respectively, and those at 2 months after lobectomy were 84 and 83.2% of baseline, respectively [12] . Comparing this data with our results, RFA seems to affect pulmonary function less than the pulmonary surgeries. Nevertheless, this study suggests that pulmonary function may decrease by up to 30% if the patients suffer from severe pleuritis or the ablated parenchymal volume is C20 cm 3 . Although decrease of pulmonary function is clinically insignificant in the majority of cases, two patients required home oxygen therapy after RFA. Thus, application of RFA should be carefully determined for patients with severely impaired pulmonary function.
There were several limitations of this study. It was based on data from only a subsection of patients who underwent RFA for lung cancer because of relatively strict inclusion criteria. The study population was heterogeneous in terms of cancer type and type of electrode used. The ablation zone volume measured by us was not necessarily precise. For example, ground-glass opacity induced by thermal damage immediately after RFA may not be clear enough to recognize, which may lead to an underestimation of the ablation zone volume. In contrast, the associated parenchymal hemorrhage, congestion, and edema, all of which may result in ground-glass opacity, may lead to an overestimation. However, such measurement errors were assumed to be too small to influence substantially the statistical outcomes. Evaluation of pulmonary function was limited to a 3-month period after RFA. However, it would be more difficult to evaluate the influence of RFA on pulmonary function at a later phase, because various other influencing factors, including additional treatment for lung cancer, cancer progression, and aging-associated regressive changes, may also be related to impaired pulmonary function.
In conclusion, pulmonary function significantly decreased 1 and 3 months after RFA. The mean proportion of VC and FEV 1 was 92.6 and 94.5% at 1 month, and 94.6 and 94.7% at 3 months, respectively, compared to baseline. The occurrence of severe pleuritis after RFA was significantly associated with impaired pulmonary function at 1 month. At 3 months, a larger ablated parenchymal volume was another significant factor.
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Appendix
Severe pleuritis and larger ablated parenchymal volume were the variables that were obtained after RFA. Thus, regrettably, those were not quite helpful in predicting impaired pulmonary function in advance. Then, additional analysis was performed to evaluate the predictive factors for the occurrence of severe pleuritis and larger ablated Table 5 .
Although there was no variable significantly increasing a risk of severe pleuritis, pulmonary emphysema had a tendency (P = 0.052) to be associated with the occurrence of severe pleuritis after RFA. The variables that increased a risk of larger ablated parenchymal volume significantly were emphysema (P = 0.029) and tumor volume C1.3 cm 3 (P = 0.011). Given that ventilation and perfusion has heat sink effect, decreased ventilation and perfusion in the emphysematous lung may explain the association between pulmonary emphysema and more extensive ablation leading to severe pleuritis and larger ablated parenchymal volume.
